Samsung's Ontruzant Becomes First Trastuzumab Biosimilar Approved In EU
Executive Summary
Samsung Bioepis is poised to grab the leading position in the trastuzumab biosimilar market in Europe as its biosimilar Ontruzant gets the European Commission's approval ahead of the competition.
You may also be interested in...
Celltrion's Trastuzumab Biosimilar Gets EC Nod
With the latest EC approval, Celltrion's trastuzumab biosimilar Herzuma is set to compete with Samsung's Ontruzant, which received approval late last year.
Celltrion's Trastuzumab Biosimilar Gets EC Nod
With the latest EC approval, Celltrion's trastuzumab biosimilar Herzuma is set to compete with Samsung's Ontruzant, which received approval late last year.
Roche: No Major M&A Needed To Offset Biosimilar Threat
Rather than buying its way out of trouble, Roche is backing its new products, notably the multiple sclerosis drug Ocrevus, the PD-L1 inhibitor Tecentriq and the lung cancer treatment Alecensa to offset the battering from biosimilar competition to some of its big-selling cancer therapies.